This article has multiple issues. Please help improve it or discuss these issues on the talk page . (Learn how and when to remove these messages)
|
Eva Feldman | |
---|---|
Occupation | Physician-scientist |
Eva Lucille Feldman is an American physician-scientist known for her work in the field of neurodegenerative diseases. She serves as the Russell N. DeJong Professor of Neurology at the University of Michigan, as well as the director of the NeuroNetwork for Emerging Therapies and ALS Center of Excellence at Michigan Medicine. She was also named the James W. Albers Distinguished University Professor of Neurology. [1]
Feldman has made notable contributions to research and clinical care in neurodegenerative diseases. Her primary focus has been on amyotrophic lateral sclerosis (ALS), Alzheimer's disease, cognitive decline, and the neurologic complications of diabetes and obesity, as well as how environmental toxins affect the nervous system. She has conducted research on developing stem cell therapies for the treatment of neurodegenerative diseases.
Feldman is a member of the Association of American Physicians and the National Academy of Medicine. She is on the National Academy of Medicine (governing and oversight) Council and a Fellow of the American Association for the Advancement of Science.
Feldman grew up in Indiana and completed her undergraduate degree in biology and chemistry at Earlham College with honors, followed by an M.S. in zoology at the University Notre Dame. [2] Feldman then went on to receive both her M.D. and Ph.D. at the University of Michigan as a Rackham Scholar. She completed her Neurology residency at Johns Hopkins, where she served as Chief Resident and received The Johns Hopkins Award for Medical Teaching and Excellence, the first neurologist to receive this award at Hopkins. [3] Dr. Feldman then returned to the University of Michigan to complete a neuromuscular disorders fellowship, with longtime mentor Dr. James Albers.
In 1988, Feldman became an assistant professor and opened her basic science laboratory in the Department of Neurology at Michigan Medicine, serving as member of the Neuroscience Program and Michigan Diabetes Research and Training Center. In 1994, she became an associate professor, and in 1998 she joined the faculty of the Cellular and Molecular Biology Program.
In 2000, Feldman became the director of the Juvenile Diabetes Research Foundation Center for the Study of Complications in Diabetes (until 2010), Director of the ALS Center of Excellence at Michigan Medicine, and a fully endowed professor, the Russell N. DeJong Professor of Neurology. In 2005, she was named the Director of Michigan Medicine's Neuropathy Center. She was appointed the inaugural Director of the A. Alfred Taubman Medical Research Institute in 2007, after U-M received a multimillion-dollar gift from A. Alfred Taubman for its creation. [4]
She currently is the principal investigator or co-Investigator of grants funded by the NIH, including the NIH Director's Transformative Research Award in 2021, as well as grants from the Centers for Disease Control and Prevention’s Agency for Toxic Substances and Disease Registry, the Juvenile Diabetes Research Foundation, and private foundations. Feldman also leads multiple clinical trials focused on understanding and treating neurological disorders, with an emphasis on ALS and neuropathy.
Feldman served as President of the Peripheral Nerve Society from 2007 to 2009 and President of the American Neurological Association (ANA) from 2011 to 2013. At that time, she was only the third woman elected as ANA President in 130 years. She was the first woman in 25 years to receive the Robert S. Schwab Award from the American Clinical Neurophysiology Society. She is also the only U-M alumnus to receive both Early and Distinguished Career Achievement Awards from the U-M Medical Alumni Society. This year, she was also given the University of Michigan's most prestigious honor, a Distinguished University Professorship, which was named after her longtime mentor James Albers, M.D., Ph.D. Among her many honors, Feldman is an elected member of the National Academy of Medicine (NAM) and Association of American Physicians, and a Fellow of the American Association for the Advancement of Science. In 2023, she was appointed to the National Academy of Medicine (governing and oversight) Council. Feldman is the Editor of the Contemporary Neurology Series and also serves on a number of editorial boards for leading scientific journals, including The Lancet Neurology , Nature Reviews Neurology , JAMA Neurology and Journal of Neurology, Neurosurgery and Psychiatry .[ citation needed ]
In 2007, the A. Alfred Taubman Medical Research Institute was founded to support the research of physician-scientists, with the goal of empowering medical scientists to expand the boundaries of scientific discovery, develop new medical therapies, and alleviate human suffering caused by diseases. Under Feldman's leadership, the Taubman Institute funded senior-level physician-scientists in a broad spectrum of diseases but with special attention on adult and childhood cancer, cardiovascular and metabolic diseases, and neurological conditions such as ALS, Alzheimer's disease and the diabetic neuropathy. The Institute's funding focused on supporting “translational” research; the kind that transforms laboratory discoveries into treatments for patients.
Feldman also established an Emerging Scholars program to support promising early-career physician scientists at the Taubman Institute, which has provided unencumbered seed funding to over 20 junior investigators, with an emphasis on improving the diversity of the clinician-scientist workforce.[ citation needed ]
Feldman served as Director of the Taubman Institute for 10 years.
Feldman has been an advocate for medical science, frequently appearing in public and media to discuss related issues. She has been a true ambassador for medical science. This was never more evident than the role she and the Taubman Institute played in the 2008 election when Michigan voters passed a constitutional amendment easing restrictions on embryonic stem cell research. Appearing on numerous television and radio programs, in newspaper articles and public speaking engagements, she was one of the main educators on the value of such research in the understanding and treatment of diseases. In the final days before the election, Dr. Feldman spoke alongside former President Bill Clinton at a large educational rally.[ citation needed ]
In the following year, Feldman announced the formation of the Consortium of Stem Cell Therapies at the Taubman Institute, the first facility to produce embryonic stem cell lines in Michigan and one of only a handful in the nation.
In the fall of 2015, under the leadership of Feldman, the Taubman Institute collaborated in the creation of the Center for RNA Biomedicine at the University of Michigan. It promotes and develops promotes and develops cross-disciplinary collaborations on RNA research across campus.
Feldman's scientific (basic science) laboratory was initially established in 1988 and was later named the Program for Neurology Research and Discovery. In the proceeding 20 years, her lab grew to over 30 scientists and was renamed The NeuroNetwork for Emerging Therapies (mneuronet.org) in 2020. The mission of Feldman's research remains the same: to advance scientific discovery and establish therapies for neurological diseases.
After initially taking over the ALS Clinic at Michigan Medicine, now the Pranger ALS Clinic, Feldman combined ALS patient care and ALS clinical and scientific research. The newly formed ALS Center of Excellence at Michigan Medicine was certified by the ALS Association. Patient care and clinical trials happen through Pranger ALS Clinic, while basic science research is conducted through the NeuroNetwork. All ALS-related activities at the separate entities are merged under the ALS Center of Excellence to build a true bench to bedside framework, now directed by Feldman, with Dr. Stephen Goutman, Director of the Pranger ALS Clinic, serving as the associate director.
Feldman's research also covers amyotrophic lateral sclerosis (ALS), an invariably fatal nerve affliction more commonly known as Lou Gehrig's disease. In fact, her work developing a stem cell therapy for ALS has resulted in the first FDA-approved human clinical trial for a stem cell treatment for this condition. The Phase 1 and 2 trials supported the safety and feasibility of transplanting up to 16 million stem cells into the spinal cord of ALS subjects. This is just one of the many influential advances that have emanated from her laboratory.
She has made national headlines for work uncovering links between ALS risk and pesticide exposures, and she and her team received a method-of-use patent in 2018 to repurpose a family of drugs, the Jakinibs, for use in ALS treatment based on her data identifying a novel mechanism by which the immune system contributes to disease progression. In October 2021, she received the NIH Director's Transformative Award as the leader of an interdisciplinary team from Michigan Medicine and the School of Public Health that employs novel approaches to “omics” clinical data with the goal of making ALS a preventable disease.
Feldman also founded the University of Michigan ALS Consortium, establishing a biorepository for ALS, which has facilitated identification of epigenetic, transcriptomic, metabolomic, and immunological unique signatures in ALS along with potential biomarkers. Her work has also identified new ALS therapeutic targets, as well as environmental toxins that are potentially risk factors for the disease.
Feldman is equally known internationally for her work in diabetes complications, particularly peripheral neuropathy. She received the Juvenile Diabetes Research Foundation Mary Jane Kugel Award twice (2003 and 2005), the American Diabetes Association Lifetime Achievement Award (2006), Endocrine Society Gerald D. Aurbach Award for Outstanding Translational Research (2017), and the Peripheral Nerve Society Alan J. Gebhart Prize for Excellence in Peripheral Nerve Research (2019).
Her efforts over the past 30 years in this area have changed practice guidelines for diagnosing early prediabetic neuropathy. Her early work developing the Michigan Neuropathy Screening Instrument (MNSI) has led to the tool's widespread global use to diagnose neuropathy.[ citation needed ] She has uncovered important roles for lipids and the metabolic syndrome in neuropathy pathogenesis in prediabetes and type 2 diabetes and is an author on the American Diabetes Association Guidelines on the treatment of diabetic neuropathy.[ citation needed ] She is currently developing risk assessment tools to inform the care of COVID-19 patients with type 2 diabetes during this health crisis as well as pandemics to come, while also studying the neurological implications of patients with Long COVID.
Feldman is involved in efforts to understand how metabolic dysfunction drives neurologic complications and impacts brain health. Feldman's lab is also exploring the effects on memory, as well as how gut health affects nerve function in both the brain and peripheral nerves.
Angiopathy is the generic term for a disease of the blood vessels. This also refers to the condition of damage or rupture of small blood vessels. The best known and most prevalent angiopathy is diabetic angiopathy, a common complication of chronic diabetes.
Diabetic neuropathy includes various types of nerve damage associated with diabetes mellitus. The most common form, diabetic peripheral neuropathy, affects 30% of all diabetic patients. Symptoms depend on the site of nerve damage and can include motor changes such as weakness; sensory symptoms such as numbness, tingling, or pain; or autonomic changes such as urinary symptoms. These changes are thought to result from a microvascular injury involving small blood vessels that supply nerves. Relatively common conditions which may be associated with diabetic neuropathy include distal symmetric polyneuropathy; third, fourth, or sixth cranial nerve palsy; mononeuropathy; mononeuropathy multiplex; diabetic amyotrophy; and autonomic neuropathy.
Peripheral neuropathy, often shortened to neuropathy, refers to damage or disease affecting the nerves. Damage to nerves may impair sensation, movement, gland function, and/or organ function depending on which nerve fibers are affected. Neuropathies affecting motor, sensory, or autonomic nerve fibers result in different symptoms. More than one type of fiber may be affected simultaneously. Peripheral neuropathy may be acute or chronic, and may be reversible or permanent.
Polyneuropathy is damage or disease affecting peripheral nerves in roughly the same areas on both sides of the body, featuring weakness, numbness, and burning pain. It usually begins in the hands and feet and may progress to the arms and legs and sometimes to other parts of the body where it may affect the autonomic nervous system. It may be acute or chronic. A number of different disorders may cause polyneuropathy, including diabetes and some types of Guillain–Barré syndrome.
Neuropathic pain is pain caused by a lesion or disease of the somatosensory nervous system. Neuropathic pain may be associated with abnormal sensations called dysesthesia or pain from normally non-painful stimuli (allodynia). It may have continuous and/or episodic (paroxysmal) components. The latter resemble stabbings or electric shocks. Common qualities include burning or coldness, "pins and needles" sensations, numbness and itching.
Neuritis, from the Greek νεῦρον), is inflammation of a nerve or the general inflammation of the peripheral nervous system. Inflammation, and frequently concomitant demyelination, cause impaired transmission of neural signals and leads to aberrant nerve function. Neuritis is often conflated with neuropathy, a broad term describing any disease process which affects the peripheral nervous system. However, neuropathies may be due to either inflammatory or non-inflammatory causes, and the term encompasses any form of damage, degeneration, or dysfunction, while neuritis refers specifically to the inflammatory process.
The Miller School of Medicine, officially Leonard M. Miller School of Medicine, is the University of Miami's graduate medical school in Miami, Florida. Founded in 1952, it is the oldest medical school in the state of Florida.
Chronic inflammatory demyelinating polyneuropathy (CIDP) is an acquired autoimmune disease of the peripheral nervous system characterized by progressive weakness and impaired sensory function in the legs and arms. The disorder is sometimes called chronic relapsing polyneuropathy (CRP) or chronic inflammatory demyelinating polyradiculoneuropathy. CIDP is closely related to Guillain–Barré syndrome and it is considered the chronic counterpart of that acute disease. Its symptoms are also similar to progressive inflammatory neuropathy. It is one of several types of neuropathy.
The Kolling Institute is located in the grounds of the Royal North Shore Hospital in St Leonards, Sydney Australia. The institute, founded in 1920, is the oldest medical research institute in New South Wales.
A paraneoplastic syndrome is a syndrome that is the consequence of a tumor in the body. It is specifically due to the production of chemical signaling molecules by tumor cells or by an immune response against the tumor. Unlike a mass effect, it is not due to the local presence of cancer cells.
Neurological disorders represent a complex array of medical conditions that fundamentally disrupt the functioning of the nervous system. These disorders affect the brain, spinal cord, and nerve networks, presenting unique diagnosis, treatment, and patient care challenges. At their core, they represent disruptions to the intricate communication systems within the nervous system, stemming from genetic predispositions, environmental factors, infections, structural abnormalities, or degenerative processes.
Clifford J. Woolf is professor of neurology and neurobiology at Harvard Medical School and director of the F.M. Kirby Neurobiology Center at Boston Children’s Hospital. He has added greatly to the understanding of pain.
Stefan R. Bornstein is the director of the Centre for Internal Medicine and the Medical Clinic and Policlinic III at the University Hospital Carl Gustav Carus of the Technical University of Dresden as well as the medical faculty's vice dean of international affairs and development and a member of the supervisory board of the University Hospital of Dresden. Furthermore, he is chair and honorary consultant for diabetes and endocrinology at King's College London. Previously, Bornstein worked as assistant director and professor of endocrinology at the University Hospital of Düsseldorf, as unit chief at the National Institutes of Health in Bethesda, Maryland and held the Heisenberg-scholarship of the Deutsche Forschungsgemeinschaft.
Jan A. Nolta is an American scientist and the director of the stem cell program at the UC Davis School of Medicine and Institute for Regenerative Cures. She is Scientific Director for the UC Davis Good Manufacturing Practice and editor of the journal Stem Cells. Nolta is known for her work with stem cell-related regenerative medicine. Nolta's current research focuses on treatment of Huntington's disease using mesenchymal stem cells. She was elected a AAAS Fellow in 2013.
Griffin P. Rodgers is the director of the National Institute of Diabetes and Digestive and Kidney Diseases, one of the 27 institutes that make up the United States National Institutes of Health. He is also the Chief of the institute's Molecular and Clinical Hematology Branch and is known for contributions to research and therapy for sickle cell anemia.
Radiation-induced lumbar plexopathy (RILP) or radiation-induced lumbosacral plexopathy (RILSP) is nerve damage in the pelvis and lower spine area caused by therapeutic radiation treatments. RILP is a rare side effect of external beam radiation therapy and both interstitial and intracavity brachytherapy radiation implants. RILP is a Pelvic Radiation Disease symptom.
Charlotte Jane Sumner is an American neurologist. She is a professor in the Departments of Neurology and Neuroscience at Johns Hopkins School of Medicine. Dr. Sumner cares for patients with genetically mediated neuromuscular diseases and directs a laboratory focused on developing treatments for these diseases. She co-directs the Johns Hopkins Muscular Dystrophy Association Care Center, the Spinal Muscular Atrophy (SMA), and the Charcot-Marie-Tooth (CMT) clinics, which deliver multidisciplinary clinical care, engage in international natural history studies, and provide therapeutics.
Peripheral mononeuropathy is a nerve related disease where a single nerve, that is used to transport messages from the brain to the peripheral body, is diseased or damaged. Peripheral neuropathy is a general term that indicates any disorder of the peripheral nervous system. The name of the disorder itself can be broken down in order to understand this better; peripheral: in regard to peripheral neuropathy, refers to outside of the brain and spinal cord; neuro: means nerve related; -pathy; means disease. Peripheral mononeuropathy is a disorder that links to Peripheral Neuropathy, as it only effects a single peripheral nerve rather than several damaged or diseased nerves throughout the body. Healthy peripheral nerves are able to “carry messages from the brain and spinal cord to muscles, organs, and other body tissues”.
Merit Cudkowicz is an American neurologist and neuroscientist who studies amyotrophic lateral sclerosis (ALS). Cudkowicz is Julieanne Dorn Professor of Neurology at Harvard Medical School, director of the ALS clinic and the Neurological Clinical Research Institute at Massachusetts General Hospital (MGH), and chair of the Department of Neurology at MGH. Cudkowicz has led several large-scale collaborations and clinical trials to test novel treatments for ALS and as of 2020, researching ways to detect early biomarkers of ALS to improve diagnosis.
Michael James Polydefkis is an American neurologist. He is a professor of neurology at Johns Hopkins University School of Medicine and co-director of the Cutaneous Nerve Laboratory. Polydefkis' research focuses on treating hATTR amyloidosis and diabetic and HIV-associated peripheral neuropathy.